Emergent BioSolutions (NYSE: EBS) adds $30M BARDA CYFENDUS order

Rhea-AI Filing Summary

Emergent BioSolutions Inc. disclosed a new government order for its anthrax vaccine CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted). On August 29, 2025, the company received Modification No. 20 to its existing BARDA AV7909 Contract with the Biomedical Advanced Research and Development Authority, providing for procurement of additional CYFENDUS doses valued at $30.0 million.

The underlying BARDA AV7909 Contract, originally effective September 30, 2016 and amended several times, supports development and procurement of this anthrax vaccine. Emergent also issued a press release on September 2, 2025 describing the modification, and filed the full text of Modification No. 20 and the press release as exhibits.

0001367644false00013676442025-09-022025-09-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 2, 2025

EMERGENT BIOSOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-33137

14-1902018

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)

Identification No.)

 300 Professional Drive,

Gaithersburg, Maryland 20879

(Address of principal executive offices, including zip code)

(240) 631-3200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 par value per share			EBS			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company     ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01    Other Events.

On August 29, 2025, Emergent BioSolutions Inc. (“Emergent”) received a contract modification (“Modification No. 20”) of the BARDA AV7909 Contract (as defined below) from the Office of the Assistant Secretary for Preparedness and Response to procure additional doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) (previously known as “AV7909”) valued at $30.0 million. This modification relates to Emergent’s AV7909 development and procurement contract with the Biomedical Advanced Research and Development Authority (“BARDA”), which became effective on September 30, 2016 (the “BARDA AV7909 Contract”) and has been modified from time to time.

The preceding description of Modification No. 20 does not purport to be complete and is qualified in its entirety by reference to the full text of Modification No. 20. Modification No. 20, with relevant redactions to protect confidential and sensitive information, is filed herewith as Exhibit 10.1 and is incorporated herein by reference. The BARDA AV7909 Contract is filed as a material agreement of Emergent as Exhibit 10.57 with Emergent’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

On September 2, 2025, Emergent issued a press release announcing the contract modification. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and incorporated herein by reference.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
10.1						Modification No. 20, effective August 29, 2025 to the BARDA AV7909 Contract.
99.1						Press release issued by Emergent BioSolutions Inc. on September 2, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			EMERGENT BIOSOLUTIONS INC.
Dated: September 5, 2025			By:			/s/ RICHARD S. LINDAHL
						Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial              Officer and Treasurer

FAQ

What contract update did Emergent BioSolutions (EBS) report in this 8-K?

Emergent BioSolutions reported receiving Modification No. 20 to its BARDA AV7909 Contract, providing for procurement of additional CYFENDUS™ anthrax vaccine doses valued at $30.0 million.

How much is the new CYFENDUS vaccine order worth for Emergent BioSolutions (EBS)?

The additional CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) doses under the BARDA contract modification are valued at $30.0 million.

Who is Emergent BioSolutions counterparty on the AV7909/CYFENDUS contract?

The counterparty is the Biomedical Advanced Research and Development Authority (BARDA), working through the Office of the Assistant Secretary for Preparedness and Response.

What is the BARDA AV7909 Contract mentioned by Emergent BioSolutions (EBS)?

The BARDA AV7909 Contract is Emergents development and procurement agreement for AV7909 (now CYFENDUS), which became effective on September 30, 2016 and has been modified multiple times.

Did Emergent BioSolutions (EBS) release a press statement about the CYFENDUS contract modification?

Yes. Emergent issued a press release on September 2, 2025 announcing the BARDA AV7909 Contract modification, which is furnished as Exhibit 99.1.

Where can investors find the full text of Emergent BioSolutions contract modification with BARDA?

The full text of Modification No. 20, with redactions, is filed as Exhibit 10.1, and the original BARDA AV7909 Contract is filed as Exhibit 10.57 to Emergents Form 10-K for the year ended December 31, 2024.